Imatinib Completed Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00251225A Study of Imatinib and Docetaxel in Prostate Cancer
NCT00427999Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
NCT00500110Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer